申请人:Fujisawa Pharmaceutical Co., Ltd.
公开号:US04581356A1
公开(公告)日:1986-04-08
New triazine derivatives represented by the formula: ##STR1## wherein R.sup.1 is a 1,2,3,4-tetrahydroquinolyl, 2-oxo-1,2,3,4-tetrahydroquinolyl, 2-oxo-1,2-dihydroquinolyl, indolyl, 2-oxoindolinyl, benzothiazolyl, 2-oxobenzothiazolinyl, 3,4-dihydro-1H-2,1-benzothiazinyl in which the S atom being optionally oxidized, or 3-oxo-2,3-dihydro-4H-1,4-benzoxazinyl, each of which may have one or more substituent(s) selected from lower alkyl, hydroxy(lower)alkyl, lower alkylamino, lower alkanoyl, cyclic lower alkanoyl, lower alkoxy(lower)alkyl, lower alkylamino(lower)alkanoyl, benzyl, benzyloxy(lower)alkyl, lower alkoxycarbonyl(lower)alkyl and 4-(2-hydroxyethyl)piperazin-1-yl-carbonylmethyl; R.sup.2 is a hydrogen, lower alkenyl, benzyl, carboxy(lower)alkyl or lower alkoxycarbonyl(lower)alkyl; R.sup.3 and R.sup.4, which may be the same or different, are each hydrogen or lower alkyl or together represent a bond; provided that when R.sup.1 is 2-oxo-1,2,3,4-tetrahydroquinolyl which is unsubstituted or substituted by a lower alkyl, then, R.sup.4 is a hydrogen or R.sup.2 is a lower alkenyl, benzyl, carboxy(lower)alkyl or lower alkoxycarbonyl(lower)alkyl; and pharmaceutically acceptable salt thereof, which are useful in the treatment of hypertension, thrombosis and ulcer in human beings and animals.
新的三嗪衍生物的化学式为:##STR1## 其中 R.sup.1 是1,2,3,4-四氢喹啉基、2-氧代-1,2,3,4-四氢喹啉基、2-氧代-1,2-二氢喹啉基、吲哚基、2-氧代吲哚基、苯并噻唑基、2-氧代苯并噻唑基、3,4-二氢-1H-2,1-苯并噻嗪基,其中 S 原子可选择性氧化,或者3-氧代-2,3-二氢-4H-1,4-苯并噁嗪基,每个基可能有一个或多个取代基,所选自较低烷基、羟基(较低)烷基、较低烷基氨基、较低烷酰基、环状较低烷酰基、较低烷氧(较低)烷基、较低烷基氨基(较低)烷酰基、苄基、苄氧(较低)烷基、较低烷氧羰基(较低)烷基和4-(2-羟乙基)哌嗪-1-基羰基甲基;R.sup.2 是氢、较低烯基、苄基、羧基(较低)烷基或较低烷氧羰基(较低)烷基;R.sup.3 和 R.sup.4,可能相同也可能不同,分别是氢或较低烷基,或者一起表示一个键;但是当 R.sup.1 是未取代或被较低烷基取代的2-氧代-1,2,3,4-四氢喹啉基时,那么 R.sup.4 是氢或 R.sup.2 是较低烯基、苄基、羧基(较低)烷基或较低烷氧羰基(较低)烷基;以及其药学上可接受的盐,用于治疗人类和动物的高血压、血栓形成和溃疡。